NCT01264445 - Safety and Immunogenicity Study of 2 Investigational Preventive HIV Vaccines | Biotech Hunter

Enrollment

147

Participants

Timeline

Start Date

February 28, 2011

Primary Completion Date

November 30, 2012

Study Completion Date

November 30, 2012

Conditions

HIV Infections

Interventions

BIOLOGICAL

Adjuvanted GSK investigational HIV vaccine formulation 1

Receive at Months 0 and 1

BIOLOGICAL

Adjuvanted GSK investigational HIV vaccine formulation 2

Receive at Months 0 and 1

BIOLOGICAL

Ad35 investigational HIV vaccine

Receive at Month 0

BIOLOGICAL

Adjuvanted GSK investigational HIV vaccine formulation 2

Receive at Months 3 and 4

BIOLOGICAL

Adjuvanted GSK investigational HIV vaccine formulation 2

Receive at Months 0, 1, and 4

BIOLOGICAL

Ad35 investigational HIV vaccine

Receive at Month 4

BIOLOGICAL

Ad35 investigational HIV vaccine

Receive at Months 0, 1, and 4

BIOLOGICAL

Placebo (saline)

(Vaccine:Placebo=28:7) Groups A, B, C, and D will all have a placebo comparator component (7 volunteers will receive placebo in each group at the specified months.)

Trial Locations (4)

Unknown

Kenya AIDS Vaccine Initiative, Nairobi

Uganda Virus Research Institute-IAVI, Entebbe

Medical Research Council, Masaka

Zambia-Emory HIV Research Project, Lusaka